Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Ships 3 Mil. Prevnar Doses; Supply On Track For 20 Mil. In 2004

This article was originally published in The Pink Sheet Daily

Executive Summary

The 3 mil. doses are a vast improvement over recent supply levels; Wyeth was shipping 715,000 Prevnar doses per month earlier this year. Filling operations have resumed at Pearl River, N.Y., and a second Wyeth bulk formulation suite has been approved by FDA.

You may also be interested in...



CDC Recommends Reinstating Third Prevnar Dose For Healthy Children

The Centers for Disease Control & Prevention states that the fourth dose of the pneumococcal conjugate vaccine should continue to be deferred until supply is adequate. Wyeth will assist physicians with a "call-back" strategy to vaccinate children who had their third dose deferred.

CDC Recommends Reinstating Third Prevnar Dose For Healthy Children

The Centers for Disease Control & Prevention states that the fourth dose of the pneumococcal conjugate vaccine should continue to be deferred until supply is adequate. Wyeth will assist physicians with a "call-back" strategy to vaccinate children who had their third dose deferred.

Wyeth Prevnar Dosing Restrictions May Be Lifted In Two Stages

CDC shows more confidence in supply availability and projects that three-dose coverage could start in the summer, followed by four-dose coverage in the fall. Agency's vaccine medical director compliments Wyeth on its response to the most recent shortage.

Related Content

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel